Nano Archive

Squalenoyl nanomedicine of gemcitabine is more potent after oral administration in leukemia-bearing rats: study of mechanisms

Reddy, Lakkireddy Harivardhan and Ferreira, Humberto and Dubernet, Catherine and Mouelhi, Sinda Lepetre and Desmaele, Didier and Rousseau, Bernard and Couvreur, Patrick (2008) Squalenoyl nanomedicine of gemcitabine is more potent after oral administration in leukemia-bearing rats: study of mechanisms. ANTI-CANCER DRUGS, 19 (10). pp. 999-1006.

Full text is not hosted in this archive but may be available via the Official URL, or by requesting a copy from the corresponding author.

Official URL:


In an earlier report, we demonstrated the superior anticancer efficacy of orally administered squalenoyl gemcitabine (SQdFdC) nanomedicine over its parent drug gemcitabine on rats bearing RNK-16 large granular lymphocytic (LGL) leukemia. In the present communication, we investigated the mechanisms behind this observation both at the cell and tissue level. The mechanisms were investigated by performing cytotoxicity, cell uptake, and biodistribution experiments. In the presence of cytidine deaminase, SQdFdC nanoassemblies resisted deamination and exerted significant anticancer activity in vitro against RNK-16 LGL leukemia cells, whereas the cytotoxicity of free gemcitabine decreased by similar to 83-fold, indicating its degradation due to deamination. Additionally, the SQdFdC showed considerably higher intracellular accumulation and retention compared with gemcitabine (P < 0.05). Unlike gemcitabine, the cellular access to SQdFdC was not influenced by nucleoside transporters. When administered orally to rats, unlike 3 H-gemcitabine, the H-3-SQdFdC absorbed slowly, but exhibited an improved pharmacokinetics and tissue distribution profile, particularly in the lymphoid organs (the major organs of metastasis). The resistance to deamination, followed by the improved pharmacokinetic and tissue distribution, and greater accumulation and retention at the level of cancer cells, are the key factors for the superiority of SQdFdC nanoassemblies over free gemcitabine against RNK-16 LGL leukemia in rats. Anti-Cancer Drugs 19:999-1006 (c) 2008 Wolters Kluwer Health vertical bar Lippincott Williams & Wilkins.

Item Type:Article
Uncontrolled Keywords:biodistribution; nanomedicine; oral delivery; RNK-16 large granular lymphocytic leukemia; squalenoyl gemcitabine
Subjects:Biomedical Science > Nanomedicine
ID Code:2695
Deposited By:Farnush Anwar
Deposited On:09 Jan 2009 10:18
Last Modified:22 Jan 2009 14:44

Repository Staff Only: item control page